Aragen Life Sciences
Aragen Life Sciences, a prominent player in the biotechnology sector, is headquartered in India and operates extensively across major regions, including North America and Europe. Founded in 2000, the company has established itself as a leader in providing integrated solutions for drug discovery, development, and manufacturing. Aragen's core offerings encompass a wide range of services, including biologics, small molecules, and custom research, distinguished by their commitment to innovation and quality. The company has achieved significant milestones, such as expanding its capabilities in biologics and securing partnerships with leading pharmaceutical firms. With a strong market position, Aragen Life Sciences is recognised for its expertise and reliability, making it a preferred partner for clients seeking comprehensive life science solutions.
DitchCarbon Score
How does Aragen Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aragen Life Sciences's score of 58 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aragen Life Sciences's reported carbon emissions
In 2023, Aragen Life Sciences reported total greenhouse gas emissions of approximately 95,440,000 kg CO2e from Scope 1, 2, and 3 sources. This includes 9,544,000 kg CO2e from Scope 1, 37,600,000 kg CO2e from Scope 2, and a significant 86,543,000 kg CO2e from Scope 3 emissions. The breakdown of Scope 3 emissions reveals major contributions from purchased goods and services (60,858,000 kg CO2e) and capital goods (11,982,000 kg CO2e). Aragen has set ambitious climate commitments, aiming for a 20% reduction in CO2 emissions intensity by 2025 compared to 2021 levels for both Scope 1 and Scope 2 emissions. Furthermore, the company has committed to achieving net-zero emissions across its entire value chain by 2050. Near-term targets include a 50.4% reduction in absolute Scope 1 and 2 emissions by FY2033, with a similar target for Scope 3 emissions. Long-term goals include a 90% reduction in absolute emissions across all scopes by FY2050, using FY2023 as the baseline year. These targets align with the Science Based Targets initiative (SBTi) and reflect Aragen's commitment to sustainable practices in the pharmaceuticals, biotechnology, and life sciences sector. The company is on track to meet its near-term targets, demonstrating a proactive approach to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 10,268,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 25,554,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aragen Life Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
